- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
- EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
- EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
- EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
- EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
- EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
- EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
- EQS-AFR: MorphoSys AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
- EQS-AFR: MorphoSys AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
MorphoSys AG (MORX:GER) closed at 18.15, 53.75% above the 52 week low of 11.81 set on Dec 28, 2022.
11.81Dec 28 202229.61Feb 02 2022
Markit short selling activity
|Market cap||621.31m EUR|
|EPS (TTM)||-25.23 |
Data delayed at least 15 minutes, as of Jan 27 2023 16:35 GMT.